Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06872853

Evaluation of Rare and Complex Tumours of the Thoraco-Abdominal and Soft Tissue District

The goal of this observational study is to collect structured data about diagnosis, treatment and follow-up of rare and highly complex neoplasms.

The study has a rerospective part that will consist in gathering data on patients accessing IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di S. Orsola from 01/01/2000 to 28/09/2017 and a prospective one ranging from 29/09/2017 to 31/12/2025.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Rare Malignant Neoplasm

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Oncology Unit, IRCCS AOUBO Policlinico di S. Orsola, Bologna, BO, Italy

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with histologic diagnosis of rare or highly complex malignant neoplasm
  • informed consent

Exclusion criteria

  • none

Treatment and study plan

diagnosis, surgery, drugs for rare neoplasms

Other

diagnostic and surgical procedures, drugs (pharmacological active substance, dose, regimen)

Primary outcomes

  1. Incidence of different malignant rare neoplasms

    Time frame: Throughout the lenght of study, an average of 10 years

    Description of types of tumours

Secondary outcomes

  1. Response rate (RR)

    Time frame: Throughout the lenght of study, an average of 10 years

    Response rate to different treatments (surgery, drugs)

  2. Local recurrence rate

    Time frame: Throughout the lenght of study, an average of 10 years

    Incidence of local recurrence

  3. Progression-free survival (PFS)

    Time frame: Throughout the lenght of study, an average of 10 years

    Progression-free survival (PFS) assessed for different types of rare malignant neoplasms

  4. Overall survival (OS)

    Time frame: Throughout the lenght of study, an average of 10 years

    OS assessed for different types of rare malignant neoplasms

Study contacts

Contact information is provided by the study sponsor or research team.

Maria A Pantaleo, MD

CONTACT

[email protected]

+39 051 214 ext. 4043

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Registry information

Official study title

Evaluation of Rare and Complex Tumours of the Thoraco-Abdominal and Soft Tissue District - Observational Study With Retrospective and Prospective Phase

Acronym: RAC

Important dates

Study start
2017
Primary completion
2025
Study completion
2025
First posted
Mar 12, 2025
Registry last updated
Mar 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.